Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 3/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716039 | 1.00 | ALDH1A1 (0.40) | ALDH1A1CYP3A4RECQLAHRPTGS1 | |
| SCHEMBL3921650 | 0.86 | PTGS1 (0.47) | ALDH1A1CYP3A4RECQLPTGS1PTGS2 | |
| SCHEMBL3921652 | 0.86 | PTGS1 (0.47) | ALDH1A1CYP3A4RECQLPTGS1PTGS2 | |
| SCHEMBL257116 | 0.81 | AHR (0.36) | AHRPTGS1PTGS2 | |
| SCHEMBL8956829 | 0.77 | ALDH1A1 (0.40) | ALDH1A1CYP3A4RECQLPTGS1PTGS2 | |
| SCHEMBL8956832 | 0.77 | ALDH1A1 (0.40) | ALDH1A1CYP3A4RECQLPTGS1PTGS2 | |
| SCHEMBL16957879 | 0.73 | AHR (0.33) | AHRPTGS1PTGS2 | |
| SCHEMBL4716666 | 0.72 | HDAC3 (0.44) | ALDH1A1CYP3A4PTGS1PTGS2BACE1 | |
| SCHEMBL4716668 | 0.72 | HDAC3 (0.44) | ALDH1A1CYP3A4PTGS1PTGS2BACE1 | |
| SCHEMBL9605421 | 0.72 | BACE1 (0.54) | ALDH1A1CYP3A4AHRPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931631-A1 | 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | Wyeth a Corporation of the State of Delaware (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007041023-A1 | 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072897-A1 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072897-A1 | Phenylaminopropanol derivatives and methods of their use | COMT, PNMT, GLS | ALDH1A1 391/4885CYP3A4 807/4885RECQL 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.